Eleanor P. Taranto, MD

Jacob S, Li F, Sacksith K, Lee K, Chakrabarti R, Jankowitz R, Taranto E, Knollman H, Makhlin I, Clark AS, Shash PD, DeMichele A, Apostolidis S Early Peripheral CD8+ T-Cell Dynamics Associated With Immune-Related Toxicity: Interim Analysis From a Prospective Cohort of Locally Advanced TNBC Receiving Neoadjuvant Chemo-immunotherapy , 2026 San Antonio Breast Cancer Symposium: 2026

Jacob S, Li F, Sacksith K, Lee K, Chakrabarti R, Jankowitz R, Taranto E, Knollman H, Makhlin I, Clark AS, Shash PD, DeMichele A, Apostolidis S Changes in Patient Reported Outcomes Associated with Immune-related Toxicity: Interim Analysis from a Prospective Cohort of Locally Advanced TNBC Receiving Neoadjuvant Chemoimmunotherapy , 2026 San Antonio Breast Cancer Symposium: 2026

Taranto E, Walinsky E, White F, Chandran D, DeLuca S, Bayne L, Brensinger C, Wileyto EP, Shirali A, Abdou Y, Anampa J, Balic M, Canzoniero JV, Chen NC, Howard F, Huppert L, Kahn A, Mainor C, Mouabbi JA, Nair V, Rimm DL, DeMichele A Quantitative HER2/ERBB2 expression in QuantifyHER (TBCRC 066), a prospective cohort study of patients with metastatic HER2 low/ultralow breast cancer initiating Trastuzumab Deruxtecan: A Pre-Planned Interim Analysis , 2026 San Antonio Breast Cancer Symposium: 2026

Stuver R, Moore ZR, Barta SK, Bhansali RS, Choa R, Epstein-Peterson ZD, Ganesan N, Ghione P, Jain S, Jacobsen E, Johnson WT, Lukowski JD, Lunning M, McCabe S, Merrill M, Moskowitz AJ, Singh S, Taranto E, Yahalom J, Savage KJ, Imber BS, Horwitz SM Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns , Haematologica: 2026

A. DeMichele, L. Bayne, E. Walinsky, L. Berry, S. Deluca, C. G. Smith, A. Chevalier, B. Ambasager, P. Sanchez, J. Heaven, E. Chislock, T. Pan, J. Graves, G. Belka, J. Wang, E. Taranto, A. Nayak, M. Feldman, A. Clark, L. Chodosh Abstract PD5-02: 5-year outcomes and ctdna findings in the clever trial targeting disseminated dormant tumor cells , Clin Cancer Res, 32(4_Supplement): 2026,PD5-02

E. P. Taranto , White, F , Chandran, D, E. Walinsky , S. Deluca , L. Bayne, E. P. Wileyto, A. Shirali, C. J. Robbins, Y. Abdou,J. Anampa, M. Balic, J. V. Canzoniero, N. C. Chen, F. Howard, L. Huppert, A. Kahn, C. Mainor, J. Mouabbi, V. Nair, T.Degeer, J. Weidler, T. McNicholas, C. Serway, J. Reischl, M. Bates, R. Monroe, D. L. Rimm, A. DeMichele Abstract PS4-03-12: Quantifyher (trial in progress): quantitative immunofluorescence and/or messenger rna to measure her2 expression in patients with metastatic breast cancer treated with trastuzumab deruxtecan (tbcrc066) , Clin Cancer Res, 32(4_Supplement): 2026,PS4-03-12

Taranto E, DeMichele A Evaluating the clinical utility of ctDNA testing to identify molecular cancer progression – lessons from SERENA-6 , NPJ Breast Cancer, 12(1): 2026,18

Taranto, E DIGEST , The Curbsiders Internal Medicine Podcast: 2026

Taranto E, Seewald NJ, Bayne LJ, Deluca S, Shih NC, Sanchez P, Nivar I, Ambasager B, Murray C, Chevalier A, Smith CG, Makhlin I, Rohn K, Goodspeed BL, Savage J, Wileyto P, Wang J, Belka G, Chislock E, Berry LR, Berry D, Nayak A, Feldman M, Clark AS, Chodosh LA, & DeMichele A. Abstract PS9-03: Circulating tumor DNA (ctDNA), dormant disseminated tumor cells (DTCs) and recurrence outcomes in breast cancer survivors on the SURMOUNT Study. , Clin Cancer Res, 31(12_Supplement): 2025,PS9-03

Taranto E, Barta S, Bhansali R. Central Nervous System Relapse in T and NK Cell Lymphomas , Curr Hematol Malig Rep, 18(6): 2023,243-251.